Gelita and Geltor to team up and develop vegan gelatine

The German company Gelita and the U.S. company Geltor are cooperating in the development of biotechnologically. They are producing collagen proteins for the vegan food market.

The long-established German company Gelita is the world market leader for collagen proteins. They are also the head pioneer on the market for animal-free collagen.

The U.S. biotech company Geltor intends to develop vegan collagen for the food and beverage market. Both companies have plenty of experience with biotechnological collagen proteins.

Collagen forms the basis for gelatine. Until now, companies obtained collagen from animal residues such as the connective tissue of pigs and cattle. Gelita has been marketing gelatine for 144 years and has since gone worldwide. Now, the company wants to enter the vegan market

Geltor is already developing animal-free collagen proteins for the skincare market. This includes Column, collagen from a marine animal, and HumaColl21, a human- developed collagen.

Premiere on the food market

“Our decision to invest in biotechnology is an excellent example of our commitment to innovation and the recognition of market needs,” says Hans-Ulrich Frech, who is responsible for collagen peptides at Gelita.

This complements the company’s existing portfolio of bioactive collagen peptides and strengthens its position as a market leader. Gelita wants to take care of the registration studies and the subsequent marketing of the vegan gelatine for the food and beverage market.

They planned the market launch for the end of 2020. These are the first consumable biotechnologically produced collagen proteins in the world.

The Medical cannabis sector is another key growth area

Another key growth area for biotechnological companies will come from medical cannabis. Medical cannabis is becoming more popular as an alternative to opioid-based pain management solutions.

The European medical cannabis market is expected to double in size over the course of 2019 and be worth $123 billion by 2028. Both cannabis investors and biopharmaceutical investors are beginning to view medical cannabis as a key growth area.

With that said, it is an emerging market and cannabis investment tools like Hemp.IM is key for both experienced and new investors in this dynamic sector.

__

(Featured image by jdn2001cn0 via Pixabay.com)

First published in BIOOKONOMIE, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.